Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
67 studies found for:    Raynaud's
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Not yet recruiting Prospective Multicenter Study on the Identification of Genetic Abnormalities Predisposing to Vasospasm From a Privileged Model: the Primary Raynaud's Phenomenon
Conditions: Primary Raynaud's Phenomenon (PR);   Genetic Mutations Causing PR;   Study of Patients and Their Relatives (With or Without Primary PR)
Intervention: Genetic: Demonstration of genetic mutations causing Raynaud's phenomenon
2 Completed PF-00489791 For The Treatment Of Raynaud's
Conditions: Raynaud's Disease;   Peripheral Vascular Disease
Intervention: Drug: PF-00489791
3 Unknown  A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon
Conditions: Raynaud's Disease;   Raynaud's Disease Secondary to Scleroderma;   Raynaud's Disease Secondary to Other Autoimmune Disease
Interventions: Drug: Nitroglycerin;   Drug: Topical AmphiMatrix
4 Unknown  Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms
Condition: Raynaud Disease
Interventions: Drug: 0.9% nitroglycerin in TAM cream;   Drug: vehicle cream
5 Recruiting "As Required" Oral Sildenafil in Raynaud's Phenomenon
Condition: Raynaud's Phenomenon
Interventions: Drug: Sildenafil 40 mg;   Drug: Sildenafil 80 mg;   Drug: Placebo
6 Completed Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon
Condition: Raynaud's Disease
Intervention: Drug: Topical organogel with nitroglycerin
7 Not yet recruiting Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome
Conditions: Scleroderma;   Raynaud's Syndrome
Interventions: Drug: Onabotulinumtoxin A;   Drug: sterile saline solution
8 Completed Dose Response to Topical Glyceryl Trinitrate in Patients With Raynaud's Phenomenon
Condition: Raynaud's Phenomenon
Interventions: Drug: placebo cream;   Drug: Glyceryl Trinitrate
9 Completed Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon
Conditions: Raynaud's Disease;   Scleroderma;   Autoimmune Diseases
Intervention: Drug: Topical AmphiMatrix with nitroglycerin (MQX-503)
10 Completed A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma
Conditions: Raynaud's Phenomenon;   Digital Ulcers;   Scleroderma
Interventions: Drug: Tadalafil;   Drug: Placebo
11 Completed Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma
Condition: Raynaud Disease
Intervention: Drug: Tadalafil
12 Completed Tadalafil for the Treatment of Raynaud's
Condition: Raynaud
Intervention: Drug: Tadalafil
13 Completed Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon
Conditions: Raynaud's Disease;   Raynaud's Disease Secondary to Scleroderma;   Raynaud's Disease Secondary to Autoimmune Disease
Intervention: Drug: MQX-503
14 Completed Lab Study of MQX-503 in Treatment of Raynaud's
Conditions: Raynaud Disease;   Raynaud Disease Secondary to Scleroderma;   Raynaud Secondary to Other Autoimmune Disease
Intervention: Drug: topical organogel with nitroglycerin
15 Completed
Has Results
Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon
Condition: Raynaud Phenomenon
Intervention: Drug: Udenafil or Amlodipine
16 Completed Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon
Condition: Raynaud's Disease
Intervention: Drug: Nitroglycerin
17 Completed Acupressure for the Treatment of Raynaud's Phenomenon
Condition: Primary Raynaud's Phenomeon
Interventions: Other: Acupressure;   Other: Acupressure dilatation;   Behavioral: education
18 Unknown  Prognostic Influence of Light Rheography Measurement of Patients With Secundary Raynaud Syndrome With Ulcers on Hands
Conditions: Raynaud's Phenomenon;   Skin Necrosis
Interventions: Drug: Tracleer;   Drug: Prostavasin
19 Completed Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator
Condition: Raynaud Disease
Interventions: Drug: Riociguat (Adempas, BAY63-2521);   Drug: Placebo
20 Recruiting Study of Acute Peripheral Vascular Effects, Pharmacokinetics, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis
Condition: Raynaud's Phenomenon Secondary to Systemic Sclerosis
Interventions: Drug: Alprostadil;   Other: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years